Published in J Invest Dermatol on November 13, 2008
HSV Recombinant Vectors for Gene Therapy. Open Virol J (2010) 0.99
A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity. J Virol (2016) 0.91
Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol (2011) 0.86
Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J Invest Dermatol (2009) 0.85
The challenge of developing a herpes simplex virus 2 vaccine. Expert Rev Vaccines (2012) 0.85
Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol (2010) 0.85
Comparison of the host immune response to herpes simplex virus 1 (HSV-1) and HSV-2 at two different mucosal sites. J Virol (2012) 0.81
Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2. Front Microbiol (2012) 0.78
An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge. PLoS One (2014) 0.77
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 17.06
Herpes simplex virus turns off the TAP to evade host immunity. Nature (1995) 5.93
Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol (1989) 5.77
Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components. J Virol (1985) 5.47
A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell (1994) 4.70
A viral inhibitor of peptide transporters for antigen presentation. Nature (1995) 4.26
An analysis of the biological properties of monoclonal antibodies against glycoprotein D of herpes simplex virus and identification of amino acid substitutions that confer resistance to neutralization. J Gen Virol (1986) 3.63
Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. J Virol (1984) 3.53
Physical and functional domains of the herpes simplex virus transcriptional regulatory protein ICP4. J Virol (1988) 3.14
The role of type specific and cross reacting structural antigens in the neutralization of herpes simplex virus types 1 and 2. J Gen Virol (1973) 2.90
Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest (1998) 2.85
An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1. J Virol (1995) 2.82
Herpes simplex viruses. Clin Infect Dis (1998) 2.68
Potent neutralizing activity associated with anti-glycoprotein D specificity among monoclonal antibodies selected for binding to herpes simplex virions. J Virol (1985) 2.42
Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection. J Virol (2002) 2.38
Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med (1998) 2.31
T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J Immunol (1998) 2.31
Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther (1998) 2.29
Oligomeric structure of glycoproteins in herpes simplex virus type 1. J Virol (1996) 2.22
Herpes simplex: insights on pathogenesis and possible vaccines. Annu Rev Med (2008) 1.99
In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis (1988) 1.92
Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J Infect Dis (2000) 1.90
Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J Virol (1994) 1.83
Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol (1992) 1.79
Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J Virol (1991) 1.73
Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis (2002) 1.72
Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. IV. Recognition and activation by cloned glycoproteins gB and gD. J Immunol (1986) 1.65
CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells. J Immunol (2001) 1.60
Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A (1999) 1.54
The prevalence of oral mucosal lesions in a population in Ljubljana, Slovenia. J Oral Pathol Med (2000) 1.53
Prospects for control of herpes simplex virus disease through immunization. Clin Infect Dis (2000) 1.51
Physical interaction between the herpes simplex virus type 1 immediate-early regulatory proteins ICP0 and ICP4. J Virol (1994) 1.45
A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis (1997) 1.44
Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol (1994) 1.42
Rapid detection of herpes simplex virus DNA in genital ulcers by real-time PCR using SYBR green I dye as the detection signal. J Clin Microbiol (2002) 1.39
Longitudinal study of genital infection by herpes simplex virus type 1 in Western Scotland over 15 years. BMJ (2002) 1.37
Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes (2004) 1.35
Herpes simplex virus (HSV)-specific human T-cell clones recognize HSV glycoprotein D expressed by a recombinant vaccinia virus. J Virol (1986) 1.33
In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis (1990) 1.31
Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J Infect Dis (1994) 1.31
First episodes of genital herpes in a Swedish STD population: a study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Infect (2000) 1.28
Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection. J Virol (1992) 1.26
Herpes simplex virus type 1 glycoproteins gB, gC and gD are major targets for CD4 T-lymphocyte cytotoxicity in HLA-DR expressing human epidermal keratinocytes. J Gen Virol (1998) 1.14
Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine (1998) 1.14
Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A (1996) 1.12
Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine (2005) 1.12
Herpes simplex virus type 1 targets the MHC class II processing pathway for immune evasion. J Immunol (2003) 1.11
Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J Virol (1998) 1.11
Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol (1994) 1.11
Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol (2001) 1.11
Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection. J Virol (2002) 1.04
Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis (1998) 1.04
Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production. J Immunol (2000) 1.03
DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2. Vaccine (1996) 1.03
Antiviral activity of herpes simplex virus vectors expressing murine alpha 1-interferon. Gene Ther (1995) 1.03
Genital herpes in young adults: changing sexual behaviours, epidemiology and management. Herpes (2005) 1.01
Changing trends in genital herpes simplex virus infection in Bergen, Norway. Acta Obstet Gynecol Scand (2000) 1.01
Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect (2004) 1.01
DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis (1996) 1.00
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine (2005) 0.98
Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector. Mol Ther (2006) 0.93
Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr Eye Res (2005) 0.93
Comparison of adjuvant efficacy of herpes simplex virus type 1 recombinant viruses expressing TH1 and TH2 cytokine genes. J Virol (2003) 0.92
A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant. Hum Gene Ther (1999) 0.90
Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules. Immunology (2002) 0.88
A tale of 2 alpha-herpesviruses: lessons for vaccinologists. Clin Infect Dis (2006) 0.88
Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein. Antiviral Res (2002) 0.86
Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs. J Invest Dermatol (2008) 0.84
The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol (2004) 0.84
Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge. J Virol (2005) 0.82
Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease. J Infect Dis (1989) 0.81
Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy for small-sized stage IA lung cancer. Ann Thorac Surg (2012) 2.23
Clinical outcomes of thoracoscopic lobectomy for patients with clinical N0 and pathologic N2 non-small cell lung cancer. Ann Thorac Surg (2012) 2.12
Human beta-defensin-3 promotes wound healing in infected diabetic wounds. J Gene Med (2009) 1.13
Enhanced susceptibility to infections in a diabetic wound healing model. BMC Surg (2008) 1.09
Validation of the European system for cardiac operative risk evaluation (EuroSCORE) in Chinese heart valve surgery patients. J Heart Valve Dis (2010) 1.04
Role of CCL5 in invasion, proliferation and proportion of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and CCR5 expression with breast cancer progression. Oncol Rep (2009) 1.03
Autologous skin transplantation: comparison of minced skin to other techniques. J Surg Res (2002) 1.02
Impaired wound healing in an acute diabetic pig model and the effects of local hyperglycemia. Wound Repair Regen (2008) 1.01
Gene transfer strategies in tissue engineering. J Cell Mol Med (2007) 1.00
In vivo gene delivery of Ad-VEGF121 to full-thickness wounds in aged pigs results in high levels of VEGF expression but not in accelerated healing. Wound Repair Regen (2005) 0.95
Detecting carcinoma cells in peripheral blood of patients with hepatocellular carcinoma by immunomagnetic beads and rt-PCR. J Clin Gastroenterol (2007) 0.94
Insulin-like growth factor-1 gene therapy and cell transplantation in diabetic wounds. J Gene Med (2008) 0.92
Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials (2012) 0.91
Improved oral bioavailability of capsaicin via liposomal nanoformulation: preparation, in vitro drug release and pharmacokinetics in rats. Arch Pharm Res (2014) 0.91
Cultured autologous fibroblasts augment epidermal repair. Transplantation (2002) 0.89
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc. Tumour Biol (2014) 0.89
Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs. Eur J Pharm Sci (2012) 0.89
Antagonism of betulinic acid on LPS-mediated inhibition of ABCA1 and cholesterol efflux through inhibiting nuclear factor-kappaB signaling pathway and miR-33 expression. PLoS One (2013) 0.87
The Bacillus anthracis arylamine N-acetyltransferase ((BACAN)NAT1) that inactivates sulfamethoxazole, reveals unusual structural features compared with the other NAT isoenzymes. FEBS Lett (2011) 0.87
Successful treatment of patients with paraquat intoxication: three case reports and review of the literature. J Zhejiang Univ Sci B (2012) 0.87
STAT3 mutations correlated with hyper-IgE syndrome lead to blockage of IL-6/STAT3 signalling pathway. J Biosci (2012) 0.87
Angelica sinensis polysaccharide nanoparticles as novel non-viral carriers for gene delivery to mesenchymal stem cells. Nanomedicine (2013) 0.86
Development of a glycoprotein D-expressing dominant-negative and replication-defective herpes simplex virus 2 (HSV-2) recombinant viral vaccine against HSV-2 infection in mice. J Virol (2011) 0.86
TRAF6 promoted the metastasis of esophageal squamous cell carcinoma. Tumour Biol (2013) 0.85
A classification method based on principal components of SELDI spectra to diagnose of lung adenocarcinoma. PLoS One (2012) 0.85
Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J Invest Dermatol (2009) 0.85
Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol (2010) 0.85
Ebstein's anomaly of the tricuspid valve with rheumatic mitral stenosis and aortic incompetence. J Heart Valve Dis (2009) 0.85
Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. Biomaterials (2013) 0.85
PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion. Asian Pac J Cancer Prev (2013) 0.84
Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs. J Invest Dermatol (2008) 0.84
Comparison of acid degumming and enzymatic degumming process for Silybum marianum seed oil. J Sci Food Agric (2013) 0.84
The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice. J Virol (2004) 0.84
Enhanced oral bioavailability and tissue distribution of a new potential anticancer agent, Flammulina velutipes sterols, through liposomal encapsulation. J Agric Food Chem (2013) 0.83
Gene therapy in wound healing. Surg Clin North Am (2003) 0.83
Chemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trials. PLoS One (2013) 0.83
Preparation and in vitro evaluation of povidone-sodium cholate-phospholipid mixed micelles for the solubilization of poorly soluble drugs. Arch Pharm Res (2010) 0.82
Role for ezrin in breast cancer cell chemotaxis to CCL5. Oncol Rep (2010) 0.82
The heterogeneous nature of polyethylenimine-DNA complex formation affects transient gene expression. Cytotechnology (2009) 0.82
Downregulation of VGLL4 in the progression of esophageal squamous cell carcinoma. Tumour Biol (2014) 0.82
Encapsulation of plasmid DNA in calcium phosphate nanoparticles: stem cell uptake and gene transfer efficiency. Int J Nanomedicine (2011) 0.82
Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles. Acta Biomater (2012) 0.82
Enhanced oral bioavailability of a sterol-loaded microemulsion formulation of Flammulina velutipes, a potential antitumor drug. Int J Nanomedicine (2012) 0.82
Novel human BTB/POZ domain-containing zinc finger protein ZBTB1 inhibits transcriptional activities of CRE. Mol Cell Biochem (2011) 0.82
Surfactant free RGO/Pd nanocomposites as highly active heterogeneous catalysts for the hydrolytic dehydrogenation of ammonia borane for chemical hydrogen storage. Nanoscale (2012) 0.82
Expression of DNA-PKcs and BRCA1 as prognostic indicators in nasopharyngeal carcinoma following intensity-modulated radiation therapy. Oncol Lett (2013) 0.81
Preparation and effects of 2,3-dehydrosilymarin, a promising and potent antioxidant and free radical scavenger. J Pharm Pharmacol (2010) 0.80
Gprc5a-deficiency confers susceptibility to endotoxin-induced acute lung injury via NF-κB pathway. Cell Cycle (2015) 0.80
Reliability and validity of simplified Chinese version of Swiss Spinal Stenosis Questionnaire for patients with degenerative lumbar spinal stenosis. Spine (Phila Pa 1976) (2014) 0.80
Hydrogen saline is protective for acute lung ischaemia/reperfusion injuries in rats. Heart Lung Circ (2012) 0.80
Gene therapy in cutaneous wound healing. Front Biosci (2007) 0.79
Formulation and pharmacokinetic evaluation of tetracycline-loaded solid lipid nanoparticles for subcutaneous injection in mice. Chem Pharm Bull (Tokyo) (2011) 0.79
Incorporating pTGF-β1/calcium phosphate nanoparticles with fibronectin into 3-dimensional collagen/chitosan scaffolds: efficient, sustained gene delivery to stem cells for chondrogenic differentiation. Eur Cell Mater (2012) 0.79
PMS1077 sensitizes TNF-α induced apoptosis in human prostate cancer cells by blocking NF-κB signaling pathway. PLoS One (2013) 0.79
Ability of ambulatory ECG-based T-wave alternans to modify risk assessment of cardiac events: a systematic review. BMC Cardiovasc Disord (2014) 0.79
[Activity of esterases and effect of genetic polymorphism in workers exposed to organophosphorus pesticides]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi (2006) 0.78
Pilot study: optical coherence tomography as a non-invasive diagnostic perspective for real time visualisation of onychomycosis. Mycoses (2009) 0.78
Cell suspension cultures of allogenic keratinocytes are efficient carriers for ex vivo gene transfer and accelerate the healing of full-thickness skin wounds by overexpression of human epidermal growth factor. Wound Repair Regen (2007) 0.78
EGFR phosphorylates and inhibits lung tumor suppressor GPRC5A in lung cancer. Mol Cancer (2014) 0.78
Stratum Corneum Tape Stripping: Monitoring of Inflammatory Mediators in Atopic Dermatitis Patients Using Topical Therapy. Int Arch Allergy Immunol (2016) 0.77
[Comparative study of perioperative complications and lymphadenectomy between minimally invasive esophagectomy and open procedure]. Zhonghua Wei Chang Wai Ke Za Zhi (2012) 0.77
Development and thermodynamic evaluation of novel lipid raft stationary phase chromatography for screening potential antitumor agents. Biomed Chromatogr (2014) 0.77
Analysis on Postoperative Efficacy of Radical Hepatectomy for Patients with Non-HBV/HCV Hepatocellular Carcinoma. Asian Pac J Cancer Prev (2015) 0.77
A new technique of ex vivo gene delivery of VEGF to wounds using genetically modified skin particles promotes wound angiogenesis. J Am Coll Surg (2011) 0.77
Long-term outcomes of surgical treatment for pulmonary carcinoid tumors: 20 years' experience with 131 patients. Chin Med J (Engl) (2012) 0.77
Effects of pesticide chemicals on the activity of metabolic enzymes: focus on thiocarbamates. Expert Opin Drug Metab Toxicol (2014) 0.77
Cytotoxic effect of novel Flammulina velutipes sterols and its oral bioavailability via mixed micellar nanoformulation. Int J Pharm (2013) 0.77
Identification and bioactivity analysis of transthyretin-like protein in amphioxus: a case demonstrating divergent evolution from an enzyme to a hormone distributor. Comp Biochem Physiol B Biochem Mol Biol (2012) 0.77
Upregulation of mediator MED23 in non-small-cell lung cancer promotes the growth, migration, and metastasis of cancer cells. Tumour Biol (2014) 0.76
Modulation of scarring in a liquid environment in the Yorkshire pig. Wound Repair Regen (2009) 0.76
Molecular cloning, characterization and expression analysis of ubiquitin protein ligase gene (As-ubpl) from Artemia sinica. Comp Biochem Physiol B Biochem Mol Biol (2013) 0.76
Cloning and expression analysis of the gene encoding fibrinogen-like protein A, a novel regeneration-related protein from Apostichopus japonicus. Mol Biol Rep (2014) 0.76
Downregulation of MED23 promoted the tumorigenecity of esophageal squamous cell carcinoma. Mol Carcinog (2013) 0.76
Acrolein, an α,β-unsaturated aldehyde, irreversibly inhibits the acetylation of aromatic amine xenobiotics by human arylamine N-acetyltransferase 1. Drug Metab Dispos (2013) 0.76
Gene therapy in the treatment of lower extremity wounds. Int J Low Extrem Wounds (2004) 0.76
Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma. Tumour Biol (2012) 0.76
Identification and expression of the elongator protein 2 (Ajelp2) gene, a novel regeneration-related gene from the sea cucumber Apostichopus japonicus. Mol Biol Rep (2014) 0.76
Gene therapy in soft tissue reconstruction. Cells Tissues Organs (2002) 0.76
Differential phosphofructokinase-1 isoenzyme patterns associated with glycolytic efficiency in human breast cancer and paracancer tissues. Oncol Lett (2013) 0.76
Self-nanoemulsifying drug delivery system of trans-cinnamic acid: formulation development and pharmacodynamic evaluation in alloxan-induced type 2 diabetic rat model. Drug Dev Res (2015) 0.75
The possible mechanisms of tumor progression via CSF-1/CSF-1R pathway activation. Rom J Morphol Embryol (2014) 0.75
Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy. J Virol (2010) 0.75
Gene delivery of PDGF for wound healing therapy. J Tissue Viability (2005) 0.75
Pseudoaneurysm of the aortic arch: A rare case report of pulmonary cancer complication. Medicine (Baltimore) (2016) 0.75
Using hyperspectral indices to measure the effect of mine dust on the growth of three typical desert plants. Guang Pu Xue Yu Guang Pu Fen Xi (2014) 0.75
No remarkable differences in rates of sensitization to common type I and IV allergens between FLG loss-of-function mutation carriers and wild-type subjects. Contact Dermatitis (2013) 0.75
Rheological behaviors of nylon 6/silica modified melamine cyanurate non-halogen flame retardant composites. J Nanosci Nanotechnol (2013) 0.75
5'-Methylthioadenosine attenuates ischemia reperfusion injury after liver transplantation in rats. Inflammation (2014) 0.75
Synthesis and biological activities of novel pleuromutilin derivatives with a substituted thiadiazole moiety as potent drug-resistant bacteria inhibitors. J Med Chem (2014) 0.75
[Application of the national diagnostic criteria of occupational mercury poisoning]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi (2011) 0.75
Expression and functional analysis of properdin in zebrafish Danio rerio. Dev Comp Immunol (2013) 0.75
Simultaneous HPLC determination of ergosterol and 22,23-dihydroergosterol in Flammulina velutipes sterol-loaded microemulsion. Biomed Chromatogr (2013) 0.75
[Cloning Hap gene from non-typeable Haemophilus influenzae and expression of Hap protein in prokaryotic cell]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi (2009) 0.75
Expression and roles of As-NUPR1 protein from Artemia sinica during embryo development and in response to salinity stress. Mol Biol Rep (2014) 0.75